• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对配体与过氧化物酶体增殖物激活受体 γ 结合的动态机制的深入了解,有助于潜在的药理学应用。

Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.

机构信息

Faculty of Life and Environmental Sciences, University of Tsukuba.

Alliance for Research on the Mediterranean and North Africa, University of Tsukuba.

出版信息

Biol Pharm Bull. 2021;44(9):1185-1195. doi: 10.1248/bpb.b21-00263.

DOI:10.1248/bpb.b21-00263
PMID:34471046
Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily, which regulates the transcription of a variety of genes involved in lipid and glucose metabolism, inflammation, and cell proliferation. These functions correlate with the onset of type-2 diabetes, obesity, and immune disorders, which makes PPARγ a promising target for drug development. The majority of PPARγ functions are regulated by binding of small molecule ligands, which cause conformational changes of PPARγ followed by coregulator recruitment. The ligand-binding domain (LBD) of PPARγ contains a large Y-shaped cavity that can be occupied by various classes of compounds such as full agonists, partial agonists, natural lipids, and in some cases, a combination of multiple molecules. Several crystal structure studies have revealed the binding modes of these compounds in the LBD and insight into the resulting conformational changes. Notably, the apo form of the PPARγ LBD contains a highly mobile region that can be stabilized by ligand binding. Furthermore, recent biophysical investigations have shed light on the dynamic mechanism of how ligands induce conformational changes in PPARγ and result in functional output. This information may be useful for the design of new and repurposed structures of ligands that serve a different function from original compounds and more potent pharmacological effects with less undesirable clinical outcomes. This review provides an overview of the peculiar characteristics of the PPARγ LBD by examining a series of structural studies focused on the dynamic mechanism of binding and the potential applications of strategies for ligand screening and chemical labeling.

摘要

过氧化物酶体增殖物激活受体 γ(PPARγ)是核受体超家族的一员,它调节涉及脂质和葡萄糖代谢、炎症和细胞增殖的各种基因的转录。这些功能与 2 型糖尿病、肥胖和免疫紊乱的发生有关,这使得 PPARγ 成为药物开发的有前途的靶点。大多数 PPARγ 功能受小分子配体结合的调节,配体结合导致 PPARγ 的构象变化,随后募集共调节剂。PPARγ 的配体结合域(LBD)包含一个大的 Y 形腔,可被各种类别的化合物占据,如完全激动剂、部分激动剂、天然脂质,在某些情况下,还可以是多种分子的组合。几项晶体结构研究揭示了这些化合物在 LBD 中的结合模式,并深入了解了由此产生的构象变化。值得注意的是,PPARγ LBD 的 apo 形式含有一个高度可移动的区域,可通过配体结合稳定。此外,最近的生物物理研究揭示了配体如何诱导 PPARγ 构象变化并产生功能输出的动态机制。这些信息可能有助于设计具有不同功能和更有效力的新型和重新利用的配体结构,从而减少不良的临床结果。本综述通过检查一系列专注于结合动态机制和配体筛选和化学标记策略的潜在应用的结构研究,概述了 PPARγ LBD 的特殊特征。

相似文献

1
Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.对配体与过氧化物酶体增殖物激活受体 γ 结合的动态机制的深入了解,有助于潜在的药理学应用。
Biol Pharm Bull. 2021;44(9):1185-1195. doi: 10.1248/bpb.b21-00263.
2
Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.作为一种 PPARα/γ双重激动剂,用于治疗非酒精性脂肪性肝病和糖尿病血脂异常的药物沙格列汀的结构基础。
Biol Pharm Bull. 2021;44(9):1210-1219. doi: 10.1248/bpb.b21-00232.
3
Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.从天然产物中合理筛选过氧化物酶体增殖物激活受体γ激动剂:心力衰竭的潜在治疗方法
Pharm Biol. 2017 Dec;55(1):503-509. doi: 10.1080/13880209.2016.1255648.
4
Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.对映异构体 PPARγ 激动剂活性差异的结构基础:S35 与备用结合位点的结合。
Biochim Biophys Acta Proteins Proteom. 2017 Jun;1865(6):674-681. doi: 10.1016/j.bbapap.2017.03.008. Epub 2017 Mar 22.
5
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.过氧化物酶体增殖物激活受体γ(PPARγ)配体结合域与新型部分激动剂复合的晶体结构:疏水口袋的一个新区域可用于药物设计。
J Med Chem. 2008 Dec 25;51(24):7768-76. doi: 10.1021/jm800733h.
6
Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.过氧化物酶体增殖物激活受体γ(PPARγ)具有多个结合位点,可容纳各种构象的配体:结构相似的PPARγ部分激动剂以不同构象与PPARγ配体结合域结合。
Bioorg Med Chem Lett. 2015 Jul 15;25(14):2758-62. doi: 10.1016/j.bmcl.2015.05.025. Epub 2015 May 22.
7
Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.通过与内源性脂肪酸的共价修饰对过氧化物酶体增殖物激活受体γ(PPARγ)激活的结构洞察。
J Mol Biol. 2009 Jan 9;385(1):188-99. doi: 10.1016/j.jmb.2008.10.039. Epub 2008 Oct 19.
8
Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.受结构生物学启发,开发了一系列人过氧化物酶体增殖物激活受体γ(PPARγ)配体:从激动剂到拮抗剂。
Int J Mol Sci. 2023 Feb 15;24(4):3940. doi: 10.3390/ijms24043940.
9
Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.在各种调节剂存在的情况下,过氧化物酶体增殖物激活受体γ配体结合域的氢/氘交换(H/D-Ex)
Protein Sci. 2006 Aug;15(8):1883-92. doi: 10.1110/ps.062103006. Epub 2006 Jul 5.
10
Structural Insights into the Loss-of-Function R288H Mutant of Human PPARγ.人源 PPARγ R288H 功能丧失突变体的结构解析
Biol Pharm Bull. 2021;44(9):1196-1201. doi: 10.1248/bpb.b21-00253.

引用本文的文献

1
extracts enhance 3T3-L1 adipocyte differentiation via CHOP inhibition and PPARγ activation.提取物通过抑制CHOP和激活PPARγ增强3T3-L1脂肪细胞分化。
Anim Cells Syst (Seoul). 2025 Jul 25;29(1):469-487. doi: 10.1080/19768354.2025.2536022. eCollection 2025.
2
Identification of PTGR2 inhibitors as a new therapeutic strategy for diabetes and obesity.鉴定前列腺素还原酶2(PTGR2)抑制剂作为糖尿病和肥胖症的一种新治疗策略。
EMBO Mol Med. 2025 May;17(5):938-966. doi: 10.1038/s44321-025-00216-4. Epub 2025 Mar 21.
3
Nephroprotective effect of pioglitazone in a Wistar rat model of adenine‑induced chronic kidney disease.
吡格列酮对腺嘌呤诱导的Wistar大鼠慢性肾病模型的肾保护作用
Exp Ther Med. 2024 Aug 7;28(4):392. doi: 10.3892/etm.2024.12681. eCollection 2024 Oct.
4
In Silico Search for Drug Candidates Targeting the PAX8-PPARγ Fusion Protein in Thyroid Cancer.计算机搜索针对甲状腺癌中 PAX8-PPARγ 融合蛋白的药物候选物。
Int J Mol Sci. 2024 May 14;25(10):5347. doi: 10.3390/ijms25105347.
5
Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists.新型苄叉-2,4-噻唑烷二酮作为部分过氧化物酶体增殖物激活受体 γ 激动剂的合成、分子对接和体内抗糖尿病评价。
Sci Rep. 2023 Nov 14;13(1):19869. doi: 10.1038/s41598-023-47157-x.
6
Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease.过氧化物酶体增殖物激活受体α在脂蛋白代谢及动脉粥样硬化性心血管疾病中的作用
Biomedicines. 2023 Oct 3;11(10):2696. doi: 10.3390/biomedicines11102696.
7
Valerenic Acid Promotes Adipocyte Differentiation, Adiponectin Production, and Glucose Uptake Its PPARγ Ligand Activity.缬草烯酸通过其过氧化物酶体增殖物激活受体γ(PPARγ)配体活性促进脂肪细胞分化、脂联素生成及葡萄糖摄取。
ACS Omega. 2022 Dec 13;7(51):48113-48120. doi: 10.1021/acsomega.2c06120. eCollection 2022 Dec 27.